Arvinas logo

BRD4 Proteolysis Targeting Chimera (PROTAC®) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects

December 1, 2016
American Society of Hematology 58th Annual Meeting and Exposition
Skip to content